Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)
2005502 citationsChristian Antoni, Arthur Kavanaugh et al.Arthritis & Rheumatismprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of Zuhre Tutuncu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zuhre Tutuncu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zuhre Tutuncu more than expected).
This network shows the impact of papers produced by Zuhre Tutuncu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zuhre Tutuncu. The network helps show where Zuhre Tutuncu may publish in the future.
Co-authorship network of co-authors of Zuhre Tutuncu
This figure shows the co-authorship network connecting the top 25 collaborators of Zuhre Tutuncu.
A scholar is included among the top collaborators of Zuhre Tutuncu based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Zuhre Tutuncu. Zuhre Tutuncu is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Chambers, Christina, Gideon Koren, Zuhre Tutuncu, Diana Johnson, & Kenneth L. Jones. (2007). Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Organization of Teratology Information Specialists (OTIS) study.. PubMed. 53(3). 409–12.14 indexed citations
Bieber, Jeffry D, Phoebe Rich, Zuhre Tutuncu, et al.. (2007). The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis.. PubMed. 34(1). 123–9.135 indexed citations
Antoni, Christian, Arthur Kavanaugh, Bruce Kirkham, et al.. (2005). Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis & Rheumatism. 52(4). 1227–1236.502 indexed citations breakdown →
11.
Genovese, Mark C., Eliza F. Chakravarty, David L. Boyle, et al.. (2005). A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis.. PubMed. 32(12). 2345–50.5 indexed citations
12.
Tutuncu, Zuhre, Gareth J. Morgan, & Arthur Kavanaugh. (2003). Anti-TNF therapy for other inflammatory conditions.. PubMed. 20(6 Suppl 28). S146–51.16 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.